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Sjo¨gren’s syndrome is a frequent auto-immune disorder with a pulmonary location in almost
10% of the patients. Although bronchial involvement is very common, most patients only
complain of cough and this involvement rarely results in severe symptoms or chronic respira-
tory failure are rarely observed.
We describe here 5 patients with severe chronic bronchiolitis revealing primary Sjo¨gren’s
syndrome. The lung involvement resulted in chronic bronchorrhea, recurrent sinusitis, diffuse
bronchiolar nodules with bronchiectasis on the CT scan, and a severe obstructive airway
pattern on lung function tests. Improvement was obtained in 4 patients with combination of
inhaled corticosteroids, inhaled long acting beta-agonists, and a low dose of erythromycin.
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Sjo¨gren’s syndrome is an auto-immune disease character-
ized by a lymphocytic infiltration of the exocrine glands.
Sjo¨gren’s syndrome can occur alone (primary Sjo¨gren’s
syndrome), or in association with other auto-immune
diseases (secondary Sjo¨gren’s syndrome). The most
frequent manifestations are an asthenia and a sicca
syndrome with a xerostomia and a xerophtalmia. Twenty to
40% of the patients may also have an extra-glandular organ
manifestation.1,2 The prevalence of a lung is not clearly
established, varying from 9 to 90% of the patients,
according to the procedure performed for evaluation.
However, clinically significant lung involvement occurs in
9% of the patients in recent series of patients with
a primary Sjo¨gren’s syndrome.3,4 Although all parts of the
respiratory system may be involved,5 airways involvement
is very frequent in Sjo¨gren’s syndrome and affects both
upper and lower airways. An infiltration of airways wall
with inflammatory cells, particularly lymphocytes and
plasmocytes, is detected in half of the patients with
a Sjo¨gren’s syndrome.6 A follicular bronchiolitis and
a lymphocytic bronchiolitis are the most common forms of
bronchiolar involvement.2 Regarding functional abnormali-
ties, the bronchiolar involvement has been mostly
described as a reduction of airflow indexes, such as
decreased MEF50 and MEF25, and has been observed in up to
90% of the patients with a Sjo¨gren’s syndrome.7 Almost half
of the patients may also have a bronchial hyperreactivity.8
On CT scans, a bronchial thickening is observed in 8%e22%
of the patients and bronchiolar nodules are observed in
6%e24% of the patients.7,9,10
Despite the high frequency of pathological or radio-
graphical defined bronchiolar disorders in Sjo¨gren’s
syndrome, a severe clinical involvement of the airways
rarely occurs and the diagnosis of a Sjo¨gren’s syndrome in
patients with chronic bronchiolar disorders is very rare.7,11
We describe here 5 patients who presented a severe
bronchiolitis associated to a chronic respiratory failure
revealing a primary Sjo¨gren’s syndrome.
Methods
This is a retrospective, observational, non-interventional
study. Patients were recruited in two university pneumology
departments with a special interest in Sjo¨gren’s syndrome
(Bichat Hospital and Saint Louis Hospital) and in a French
center commonly in charge of Sjo¨gren’s syndrome (Rheuma-
tology department, BiceˆtreHospital). We identified all
patients diagnosed with a Sjo¨gren’s syndrome that was
revealed by a chronic bronchiolitis. To be included, the
patients had to present clinical signs of a severe bronchiolitis,
diffuse bronchiolar nodules evidenced on a CT scan and at
least one of the following objective criteria of primary Sjo¨g-
ren’s syndrome: a salivary lymphocytic infiltration of the
salivary glands with a Chisholm score  3 or the presence of
anti-SSA or anti-SSB antibodies. Exclusion criteria at diagnosis
were : a definite connective tissue disease other that Sjo¨g-
ren’s syndrome, AIDS, a sarcoidosis, a graft versus host
disease, a past head and neck radiation therapy, a hepatitis C
infection and a concomitant use of anticholinergic drugs.The clinical charts of the patients were reviewed and
the following items were analyzed: age at diagnosis, age at
onset of the first symptoms, gender, history of persistent
purulent rhinosinusitis, smoking history, history of child-
hood respiratory infections or pulmonary tuberculosis,
atopy or asthma, connective tissue disorders, symptoms of
gastroesophageal reflux, infertility, and familial history of
immunodeficiency or pulmonary sepsis. Lung function tests
at diagnosis and during the follow-up were recorded.
Outcome data were recorded until death or the last
scheduled visit.
All available high resolution computed tomographies
(HRCT) of the thorax were centrally reviewed by an expe-
rienced chest radiologist (MPD). A lesional score was given
using a semi-quantitative grading system.12 A score from
0 (no lesion) to 3 was attributed to each lobe and to each
lingula and culmen. The maximum theoretical score was
then 18.
Data were collected on a standardized and anonymous
collection form. For this retrospective, observational, non-
interventional analysis of medical records, French author-
ities do not require a specific approval of an Internal Review
Board or the consent of the patients. Data are reported as
median [extremes].
Case reports
Bichat and Biceˆtre hospitals databases retrieved 101
patients with primary Sjo¨gren’s syndrome associated to
a “pulmonary disease”. After review, only 4 patients ful-
filled the inclusion criteria. One additional patient was
referred by Saint Louis hospital, without the use of a data-
base. Patients were 4 women and 1 man. The median age at
diagnosis was 58 years [38e70]. All patients presented with
a prominent dyspnea lasting from 1 to 144 months (median
10 months) at the time of diagnosis associated to a cough
and chronic sputum for 4 of them (Fig. 1). Four patients had
required a chronic nasal oxygen therapy at the time of
diagnosis because of a severe chronic hypoxemia (Fig. 1).
Three patients had declared a history of repeated upper
airway infections lasting since 1e14 years. Lung sounds
were always abnormal for all patients. No patient had
received anticholinergic drug.
For each patient, a lung CT scan (Figs. 1 and 2) had
evidenced diffuse and profuse centrilobular micronodules
associated with mild bronchiectasis. Alveolar consolida-
tions had been detected at diagnosis in 3 patients, and
disappeared on further CT scans, as patients were treated
with antibiotics and physiotherapy. For 4 of the patients,
a sinus CT scan had revealed a sinusitis without osteolytic
lesion.
In all patients, the pulmonary function tests had evi-
denced an obstructive pattern, defined as a reduced FEV1/
FVC ratio <70%, in all the patients (Table 1).
Bronchial aspirates had grew with Pseudomonas aerugi-
nosa in one patient, and with Staphylococcus aureus in one
other patient. Mycobacterial and fungal cultures were
negative for all patients. Broncho-alveolar lavage was
performed in 4 patients and revealed an increased cellu-
larity (950 cells/mm3 [500e25400]) with prominent neu-
trophilia (80% [39e100]).
Figure 1 Evolution of PaO2, dyspnea, FEV1, and CT lesional score of the five patients from diagnosis to the last follow-up visit.
Dyspnea was assessed using NYHA scale. Lesional score was defined according to Taouli et al.12 Among the 5 patients, 4 were
improved on all criteria analyzed.
132 R. Borie et al.A surgical lung biopsy had been performed in one patient
at the time of surgery for thymoma. Respiratory failure was
considered too severe for the 4 other patients to perform
a surgical lung biopsy.
For all patients, common etiologies of chronic bronchi-
olar disorders had been ruled out: serum immunoglobulins
levels were normal or increased; a1-antitrypsin levels; the
search for cystic fibrosis was negative and the ciliary
motility on nasal mucosa biopsy was normal. None of the
patients had declared a history of childhood respiratory
infections (pertussis, pneumonia, or measles), or a history
of pulmonary tuberculosis. None of the patients had an
evidence of an inflammatory bowel disease, or a yellow nail
syndrome.
All 5 patients were considered as having a primary
Sjo¨gren’s syndrome according to the Fox criteria13 and 4 of
them according to the tree procedure of the revised
AmericaneEuropean Consensus Group criteria (AECC)
(Table 2).14 Four patients had extra-glandular manifesta-
tions of their Sjo¨gren’s syndrome. None of the patients hadFigure 2 CT scans of the chest from patient 4 from diagnosis (A
dramatic clinical improvement was noted 6 months after the init
graphical attenuation of bronchiolar micronodular lesions.other definite connective tissue disorder. All patients had
positive antinuclear antibodies. Anti-SSA antibodies were
present in 2 patients. Other auto-antibodies were less
frequently detected.
The median follow-up was 78 months [35e106]. All
patients had been treated with inhaled corticosteroids and
long acting beta-agonists associated with chest physio-
therapy to improve the drainage of the bronchial secre-
tions. Three patients had been treated with erythromycin
(500 mg/d). Three patients had been dramatically
improved with their therapy and weaned from oxygen
therapy (Fig. 1).Three patients had recurrent respiratory
infections during follow-up, and one of them had died from
pneumonia.
Patient 1 (Fig. 1, diamond)
Patient 1 was a 58-year-old woman, 60 year-pack former
smoker. She presented with a dyspnoea and chronic
expectorations since 1 year. She also presented arthralgias,), to the last CT scan of follow-up visit (B), 76 months later. A
iation of erythromycin therapy followed by impressive radio-
Table 1 Pulmonary Function Tests at diagnosis of five patients with severe bronchiolitis and primary Sjo¨gren’s syndrome. Data
are expressed as measured values and percentage (CECA 199327).
Patient TLC L (%) RV L (%) FEV1 L/s (%) FEV1/FVC
ratio
MEF
75, 50, 25
L/s (%)
DLCO
mmol/min/kPa
(%)
PaO2 at
rest (mmHg)
PaCO2 at
rest (mmHg)
n1 7.23 (140%) 3.6 (195%) 1.89 (72%) 0.64 2.52, 1.09, 0.25
(45, 28, 17%)
2.06 (32%) 60 43
n2 2.83 (82%) 1.51 (100%) 1.14 (39%) 0.52 0.59, 0.46, 0.13
(10, 11, 7%)
NA 73 37
n3 2.71 (64%) 1.28 (70%) 0.66 (43%) 0.59 1.43, 0.63, 0.10
(30, 10, 10%)
3.35 (52%) 64 40
n4 8.84 (108%) 4.03 (159%) 2.13 (52%) 0.44 1.84, 0.65, 0.14
(22, 12, 6%)
3.42 (30%) 53 40
n5 2.56 (70%) 1.61 (100%) 0.51 (31%) 0.6 0.50, 0.22, 0.12
(10, 7, 11%)
NA 60 42
Sjo¨gren’s syndrome and bronchiolitis 133associated to oral and ocular symptoms and ocular signs.
Sjo¨gren’s syndrome was confirmed by histopathology. She
also presented an auto-immune hepatitis and thyroiditis.
Pulmonary function tests revealed an irreversible obstruc-
tive pattern with a pulmonary distension. A CT scan
revealed lower lung zone predominant micronodules, with
limited bronchiectasis and maxillary sinusitis. Broncho-
alveolar lavage revealed 500 cells/mm3, with 88% of
neutrophils without any pathogen. A cystic fibrosis was
excluded by normal sweats chloride testing.
She was treated with low dose of prednisone and azathio-
prine for her by auto-immune hepatitis. After 36 months of
follow-up, she presented a dramatic improvement (the PaO2
increased from 60 to 74 mm Hg) with only one respiratory
exacerbation secondary to S. maltophilia infection.
Patient 2 (Fig. 1, triangle)
Patient 2was a non-smoker 30 year oldwoman. She presented
with a dyspnoea and chronic expectorations since 14 years.
She also presented with arthralgias, a Raynaud phenomenon,
oral and ocular symptoms and ocular signs, Sjo¨gren’s
syndrome was confirmed by histopathology. The antinuclear
antibodies were at 1/1280 without specific auto-antibodies.
Pulmonary function tests revealed an irreversible obstructive
pattern with increase ratio RV/TLC (residual volume/total
lung capacity). CT scan revealed micronodules with upper
lobes predominance, with limited bronchiectasis and
a maxillary sinusitis. Bronchial aspirates grew with pseudo-
monas aeruginosa. Cystic fibrosis was excluded by normal
sweats chloride testing, normal transepithelial nasal poten-
tial difference, and absence of the 31 main mutations of
CFTR. The ciliarymotility was normal on nasalmucosa biopsy.
She was treated with erythromycin during 18 months and
azithromycin during 10 months with a partial improvement.
During the 96 months of follow-up she presented 2 to 3
respiratory infections per year. Repeated sputum analysis
grew with E. Coli and H Influenza.
Patient 3 (Fig. 1, circle)
Patient 3 was a non-smoker 70-year-old woman. She was
treated for ischemic cardiopathy. She presented witha dyspnoea since 1 year. She also presented with oral and
ocular symptoms and ocular signs. Sjo¨gren’s syndrome was
confirmed by the presence of anti-SSA antibodies. Pulmo-
nary function tests revealed a reversible obstructive
pattern mixed with restrictive pattern. CT scan revealed
pulmonary peripheral micronodules, with limited bronchi-
ectasis and a maxillary sinusitis. Broncho-alveolar lavage
revealed 700 cells/mm3, with 39% neutrophils, without any
pathogen. A cystic fibrosis was excluded by normal sweats
chloride testing, normal transepithelial nasal potential
difference, and the absence of the 31 main mutations of
CFTR. The ciliary motility was normal on the nasal mucosa
biopsy.
Beta-blockers were withdrawn with a partial improve-
ment after a follow-up of 78 months. There was no respi-
ratory exacerbation but the patient suffered from
recurrent myocardial infarction.Patient 4 (Fig. 1, square)
Patient 4 was an 8 pack-year former smoker, 58-year-old
man. He had received a mediastinal radiotherapy for
a Hodgkin’s disease, 19 years before diagnosis. He was
considered as cured from his Hodgkin’s disease. He pre-
sented with a dyspnoea and chronic expectorations since 13
year. He also presented with arthralgia and oral symptoms.
Sjo¨gren’s syndrome was confirmed by the presence of anti-
SSA antibodies and by histopathology. Pulmonary function
tests revealed a severe irreversible obstructive pattern. CT
scan revealed diffuse pulmonary micronodules and a pan-
sinusitis (Fig. 2). Broncho-alveolar lavage revealed 950
cells/mm3, with 83% neutrophils, without any pathogen. A
cystic fibrosis was excluded by normal sweats chloride
testing, normal transepithelial nasal potential difference,
and the absence of the 31 main mutations of CFTR. The
ciliary motility was normal on the nasal mucosa biopsy.
He experienced 3 respiratory infections in the first 6
months of follow-up without any identified pathogen. A
chronic sinusitis required surgical maxillary drainage. The
patient received erythromycin (500 mg/day) during 76
months with a dramatic improvement (Fig. 1). He devel-
oped a diffuse large B cell lymphoma after 36 months of
follow-up, treated with chemotherapy and an autologous
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134 R. Borie et al.stem cell transplantation. After a total of 106 months of
follow-up he is still in remission of bronchiolits and
lymphoma.
Patient 5 (star)
Patient 5 was a non-smoker 61-year-old woman. A thymoma
was diagnosed concomitantly to a chronic bronchiolitis. She
presented with a dyspnoea and expectorations since 7
years. She also presented with oral and ocular symptoms.
Sjo¨gren’s syndrome was supported by a salivary glands
histopathology. She also presented with myasthenia gravis
and auto-immune thyroiditis. Pulmonary function tests
revealed an irreversible obstructive pattern mixed with
restrictive pattern. CT scan revealed peripheral micro-
nodules, with limited bronchiectasis and pansinusitis.
Broncho-alveolar lavage revealed 2500 cells/mm3, with
100% neutrophils, without any pathogen. A cystic fibrosis
was excluded by normal sweats chloride testing, a normal
transepithelial nasal potential difference, and absence of
the 31 main mutations of CFTR.
Lung surgical biopsies, performed at the time of the
thymoma surgery, evidenced a cellular bronchiolitis char-
acterized by a peribronchiolar lymphoplasmacytic infiltra-
tion. She did not received any specific treatment for her
bronchiolitis during 60 months. She was referred to Bichat
hospital because of a severe lung function alteration and
recurrent respiratory infections. She died from sepsis after
4 months of erythromycin, probably due to a Pseudomonas
pneumonia.
Discussion
This report describes 5 patients with a severe obstructive
lung disease consistent with a chronic bronchiolitis,
in whom the bronchial disease led to the diagnosis of
a Sjo¨gren’s syndrome. Although some degree of histological
or radiographical bronchiolar involvement is common in
patients with a primary Sjo¨gren’s syndrome, this clinical
syndrome has not been previously individually described,
despite a potential improvement with therapy.
We believe that the diagnosis of primary Sjo¨gren’s
syndrome was assesed in these 5 patients. All of them ful-
filled the Fox criteria for probable primary Sjo¨gren’s
syndrome.13 Four of the 5 patients fulfilled the tree
procedure of AECC criteria.14 The fifth patient did not fulfil
this procedure, because an objective evaluation of salivary
gland function had not been performed. However this
patient had oral and ocular symptoms associated with
a histopathology score of 3 and elevated antinuclear anti-
bodies titer (1/2560), that reinforced the diagnosis of
a probable Sjo¨gren’s syndrome. Indeed the sensitivity and
specificity of the AECC classification tree are 96.1 and
94.2% respectively, the clinical judgement of an experi-
mented observer is still considered as the gold standard for
the diagnosis of Sjo¨gren’s syndrome [14]. Patient 4 had
received mediastinal radiotherapy 19 years before the
diagnosis of Sjogren’s syndrome. Sicca syndrome may be a
long-term side effect of mediastinal radiotherapy. However
the patient 4 also had arthralgias, a positive rheumatoid
factor, high level of antinuclear antibodies with anti-SSA
Sjo¨gren’s syndrome and bronchiolitis 135specificity, and lymphocytic infiltration of salivary glands
(Chisholm score at 3) making the diagnosis of Sjo¨gren’s
syndrome highly probable.
All the patients presented with typical centrilobular
micronodules on the CT scan (Fig. 2) and a severe
obstructive pattern on lung function tests, indicating
a bronchiolar disorder. Normally, bronchiolitis should have
been confirmed by an histological proof. Even if the
severity of the respiratory insufficiency did not aloud
a surgical lung for 4 of the patients, it was performed in one
patient and a cellular bronchiolitis was diagnosed.
We believe that the bronchiolar disorder observed in
these patients is not fortuitous but directly linked to
primary Sjo¨gren’s syndrome. Indeed alternative etiologies
of bronchiolitis have been ruled out in every patient by
experienced pulmonologists. Furthermore mild bronchiolar
abnormalities have been consistently detected in patients
with a Sjo¨gren’s syndrome. Several studies have evidenced
a mild airway obstruction in patients with a Sjo¨gren’s syn-
drome7,15e17 and in series of Sjo¨gren’s syndrome patients
without respiratory complaints, CT scans evidenced bron-
chiectasis in 5e46% of the patients10,18 and centrilobular
micronodules in 6e29% of the patients.7,9,12 We still have
poor data regarding the morphology of the airways in
Sjo¨gren’s syndrome. Bronchial biopsies showed an
increased number of CD4 positive T lymphocytes in the
proximal airways.6 Transbronchial lung biopsies17,19 and
surgical lung biopsies2,20 both showed a peribronchiolar and
an interstitial inflammation. Two main bronchiolar histo-
logical subtypes have been described in Sjo¨gren’s syndrome
patients: a lymphocytic bronchiolitis without follicles
formation seems to be the most frequent abnormality,20,21
whereas a follicular bronchiolitis, more or less associated
with a lymphoid interstitial pneumonia, is rare.19,22 A
diffuse panbronchiolitis has been described in one Japa-
nese patient.23 A constrictive bronchiolitis does not seem to
be a feature of Sjo¨gren’s syndrome.
Despite the frequency of a bronchiolar involvement in
Sjo¨gren’s syndrome, usually bronchial involvement does not
induce a severe clinical syndrome. Most patients only suffer
only from dry cough.7 This makes our series of patients
highly original as it demonstrates that an airway involve-
ment can be responsible for a severe chronic broncho-
pulmonary failure in patients with a Sjo¨gren’s syndrome.
Furthermore this study demonstrates that a chronic bron-
chiolitis may reveal a Sjo¨gren’s syndrome. Among the
connective tissue diseases, bronchiolitis has been reported
mostly in rheumatoid arthritis,24 and exceptionally in
systemic sclerosis,25 and lung involvement may precede the
diagnosis of rheumatoid arthritis, although this rarely
occurs (12% of patients in a recent series).24
Interestingly, recurrent infections of the upper respira-
tory tract were a key feature in 4 out the 5 patients
studied. Recurrent infections of the upper and lower
respiratory tracts are known manifestations of Sjo¨gren’s
syndrome.
Our data indicate that a specific therapy may be of value
in a Sjo¨gren’s syndrome associated to a bronchiolitis. Here,
one patient improved with erythromycin and one other
patient with an immunosuppressive therapy (corticoste-
roids and azathioprine). We do not believe that the bron-
chiolitis would have spontaneously improved in ourpatients, as no patient was cured after 6 months of follow-
up. Furthermore, patient 5 did not receive any therapy
during the 76 months proceeding the diagnosis and no
spontaneous improvement (CT, functional or clinical)
occurred. Only few data exist on the effect of therapy on
a bronchiolitis in Sjo¨gren’s syndrome. We believe that
a therapeutic trial with macrolides should be performed in
patients with a symptomatic bronchiolitis in the context
of a Sjo¨gren’s syndrome as it could be successful. Recently
a patient cured with Rituximab, an anti CD20 monoclonal
antibody, has been reported.26
In conclusion, a chronic bronchiolitis with a severe lung
function alteration may be the first manifestation of
a Sjo¨gren’s syndrome. Physicians must be aware on this
specific involvement of the bronchial tree as a treatment
with macrolides, inhaled corticosteroids and inhaled bron-
chodilatators, may strongly improve the respiratory status
of these patients.
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